Lipid metabolic vulnerabilities of multiple myeloma

  • Clin Exp Med. 2023 Nov;23(7):3373-3390. doi: 10.1007/s10238-023-01174-2.
Roberta Torcasio  #  1  2 ,  Maria Eugenia Gallo Cantafio  #  1 ,  Raissa Kaori Ikeda  1  3 ,  Ludovica Ganino  1 ,  Giuseppe Viglietto  1 ,  Nicola Amodio  4
Affiliations
  • 1. Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Viale Europa, Campus Germaneto, 88100, Catanzaro, Italy.
  • 2. Department of Biology, Ecology and Heart Sciences, University of Calabria, Arcavacata Di Rende, Cosenza, Italy.
  • 3. Centro Universitário São Camilo, São Paulo, Brazil.
  • 4. Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, Viale Europa, Campus Germaneto, 88100, Catanzaro, Italy. [email protected].
  • # Contributed equally.
Abstract

Multiple Myeloma (MM) is the second most common hematological malignancy worldwide, characterized by abnormal proliferation of malignant plasma cells within a tumor-permissive bone marrow microenvironment. Metabolic dysfunctions are emerging as key determinants in the pathobiology of MM. In this review, we highlight the metabolic features of MM, showing how alterations in various lipid pathways, mainly involving Fatty Acids, Cholesterol and Sphingolipids, affect the growth, survival and drug responsiveness of MM cells, as well as their cross-talk with other cellular components of the tumor microenvironment. These findings will provide a new path to understanding the mechanisms underlying how lipid vulnerabilities may arise and affect the phenotype of malignant plasma cells, highlighting novel druggable pathways with a significant impact on the management of MM.

Keywords
Cholesterol; Fatty acids; Lipid metabolism; Metabolic reprogramming; Multiple myeloma; Sphingolipids.
Products